Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Hemodialysis

In brief

Cognitive decline is increasingly recognized among patients receiving maintenance hemodialysis (HD). This can include trouble remembering, slower thinking or mentally feeling foggy. This research is being done to determine if a new medication (AV-001) can protect the brain from injury caused by hemodialysis by strengthening blood vessels in the brain and reducing inflammation. If successful, this research could lead to better protection for the brains of people undergoing regular dialysis, potentially reducing the risk of cognitive decline and stroke.

Key facts

Study ID

NCT07234890

Run by

London Health Sciences Centre Research Institute

People needed

60

Starts

2025-12-16

Expected to finish

2027-12-31

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide informed consent
• Male and non-pregnant female patients (>18 years old)
• HD for ≥ 3 months
• Thrice weekly HD schedule

You may not qualify if…

• HD <90 days
• Contraindication to MRI
• Established severe cognitive impairment (Montreal Cognitive Assessment test (MoCA) <18 or formal diagnosis of dementia)
• Previous clinical stroke
• Pregnancy, breastfeeding, or intending pregnancy
• Intradialytic hypotension event (defined as: drop in SBP ≥40mmHg + symptoms + intervention) in previous month as evidenced by HD record

Where it is running

• London Health Sciences Centre — London, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.